What will it take to get institutional investors interested in life sciences again?

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
What will it take to get institutional investors interested in life sciences again?
Go to paperABSTRACT: With the European biotechnology market nearing a…


Growth of Indian biotech companies, in the context of the international biotechnology industry

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Growth of Indian biotech companies, in the context of the international biotechnology industry
Go to paperABSTRACT: The paper discusses the evolution and…


Technology transfer in the biomedical sciences: The Medical Research Council approach

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Technology transfer in the biomedical sciences: The Medical Research Council approach
Go to paperABSTRACT: This paper describes why the UK Medical Resear…


New CMS Guidance for Biotech Industry On Coverage With Evidence Development: It’s All About The Outcomes

This is a guest post from Robert E. Wanerman, a member of Epstein Becker Green’s Health Care and Life Sciences practice. Do you have a response to Robert’s post? Respond in the comments section below. For many biotech manufacturers, obtaining Medicare coverage is a significant milestone in commercializing an item or service. Although Medicare coverage […]


New Years Bio-Pharmaceutical Resolution To Nurture MSME Innovation

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. At the start of a bright and shiny new year in 2015, I am thinking about my own New Years resolutions as well as one that I would […]


PatentDrop.com posts public-domain inventions

Patents require regular ‘maintenance’ payments to keep them in force. Because the cost of maintaining large patent portfolios can be substantial, many companies elect to abandon patents that they feel are not worth pursuing. Sometimes these patents are abandoned because they are outside a company’s focus, and in other cases they may represent markets too small for […]


Patenting human genes and mutations: A personal perspective

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Patenting human genes and mutations: A personal perspective
Go to paperABSTRACT:
The Journal of Commercial Biotechnology is a unique forum for all thos…


Biogenerics 2007: How far have we come?

Journal of Commercial Biotechnology
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Biogenerics 2007: How far have we come?

Go to paper

ABSTRACT: The recent approval of a follow-on version of Pfizer’s Genotropin (recombinant human growth hormone) signalled the beginning of the end of an era in which biopharmaceuticals enjoyed immunity from competition even after expiration of their patent protection. This paper describes many of the key scientific challenges facing the nascent ‘biogenerics’ industry and the evolving regulatory framework that will shape its competition with innovator companies…

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website